Brief: Ultimovacs Completes Exploratory Phase I TENDU Study Of TET Vaccine Technology Platform

Zelluna ASA

18/12/2023 06:10

Dec 18 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * ANNOUNCES COMPLETION OF EXPLORATORY PHASE I TENDU STUDY OF
TET
VACCINE TECHNOLOGY PLATFORM MEETING THE PRIMARY ENDPOINT
    * DOSE-ESCALATION, FIRST-IN-HUMAN PHASE I TRIAL SHOWED GOOD
SAFETY
AND TOLERABILITY ACROSS ALL DOSE-COHORTS, MEETING PRIMARY
ENDPOINT

Source text for Eikon:  ID:nGNE9BQjPW 
Further company coverage:  ULTI.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))